Key Takeaway
Can you take tirzepatide with SSRIs like Zoloft or Lexapro? Complete drug interaction guide covering safety, absorption effects, and timing recommendations.
Tirzepatide and antidepressants are commonly used together, and the Zepbound and Mounjaro labels (revised 08/2026) list no specific interaction with any antidepressant. What the labels do say, in section 7.2, is that tirzepatide delays gastric emptying and "has the potential to impact the absorption of concomitantly administered oral medications," that caution should be exercised, and that patients on oral drugs that depend on threshold concentrations or have a narrow therapeutic index should be monitored. No pharmacokinetic study of tirzepatide with any antidepressant has been published as of September 5, 2026, so "generally compatible" means "no documented problem," not "proven safe."
How Tirzepatide Differs From Other GLP-1 Drugs
Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin receptors rather than one. This dual mechanism drives its strong efficacy for weight loss (a mean 20.9% reduction at week 72 on 15 mg in the SURMOUNT-1 trial[1], per the Zepbound label) and blood sugar control.
Regarding drug interactions, the relevant effect is slowed gastric emptying. A 2024 systematic review in Drug Safety (22 reports plus 6 labels) found that GLP-1 receptor agonists lowered the peak concentration and delayed the time to peak of several oral drugs (warfarin, oral contraceptives, acetaminophen, ACE inhibitors, statins, digoxin) without a clinically significant change in total exposure. Antidepressants were not among the drugs studied, so the same pattern is assumed rather than demonstrated.
Compatibility With Common Antidepressants
SSRIs
Sertraline, fluoxetine, citalopram, escitalopram and paroxetine are not listed as interacting drugs on the Zepbound or Mounjaro labels, and the general oral-absorption caution in section 7.2 is the only label guidance that applies. Correction, September 2026: an earlier version said these SSRIs were "considered compatible"; no label or study makes that statement, so it has been reworded. Both tirzepatide and certain SSRIs (particularly sertraline) can cause nausea, so your provider may suggest staggering the start of each medication to isolate which one causes any GI discomfort.
SNRIs
Duloxetine and venlafaxine are not listed as interacting drugs on the tirzepatide labels. Correction, September 2026: an earlier sentence reasoned that venlafaxine extended-release formulations would be unaffected by delayed gastric emptying; that was speculation without a pharmacokinetic study and has been removed.
Bupropion
Bupropion is uniquely positioned among antidepressants because it tends to be weight-neutral or promote mild weight loss. No interaction with tirzepatide is listed on the labels. Correction, September 2026: a sentence about "some clinicians" pairing bupropion with GLP-1 agonists was unsourced and has been removed.
Mirtazapine
Mirtazapine (Remeron) is associated with significant appetite stimulation and weight gain. Patients taking mirtazapine alongside tirzepatide may find that the medications partially counteract each other's effects on appetite. Discuss this dynamic with your provider to ensure your treatment plan is aligned.
Mental Health Considerations During Weight Loss
Rapid weight loss, regardless of the method, can affect emotional well-being. Body image shifts, changes in social dynamics, and altered relationships with food can all trigger psychological responses. If you're taking antidepressants, these changes deserve attention.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Correction, September 2026: an earlier version stated that the SURMOUNT-4 trial[2] "specifically measured quality of life." SURMOUNT-4 (JAMA 2024) was a weight-maintenance trial: after a 36-week lead-in, people who continued tirzepatide lost a further 5.5% while those switched to placebo regained 14.0%. Its abstract reports no quality-of-life figures, so that claim has been removed. Individual experiences vary, and ongoing mental health monitoring during significant weight loss is always wise.
What the label says about oral medicines (section 7.2, revised 08/2026)
The Zepbound label, seen September 5, 2026, states: "ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications." It continues that caution should be exercised, and that prescribers should "monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin)." The Mounjaro label carries the same section 7.2 language. The one oral-drug class with specific instructions is hormonal contraceptives: switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Antidepressants are not named anywhere in section 7. For comparison, the Wegovy label (06/2026) reports that semaglutide 1 mg did not affect the absorption of the oral medicines tested in its clinical pharmacology trials, though the semaglutide tablet raised levothyroxine exposure by 33%.
Update: the suicidality warning was removed from the Zepbound label in February 2026
Earlier versions of this page said the tirzepatide label tells patients to be monitored for mood changes. That was true of the Zepbound label through 2025, which carried a "Suicidal Behavior and Ideation" warning as a class precaution. The label revised in 02/2026 removed it, and the 08/2026 label lists "Suicidal Behavior and Ideation (Removed) 02/2026" under Recent Major Changes. The removal reflects the label review, not a new trial of people taking antidepressants; tirzepatide's obesity trials excluded people with recent severe psychiatric illness, so they cannot rule out effects in that group. The practical advice does not change: anyone with a mood disorder who starts tirzepatide should tell both prescribers and report new or worsening symptoms.
Evidence on oral-drug absorption with GLP-1 agonists (Drug Safety, 2024)
The most complete published review of this question is a 2024 systematic review in Drug Safety (Calvarysky et al., volume 47, pages 439 to 451) covering 22 reports and 6 product labels. Across the oral drugs studied with GLP-1 receptor agonists, including warfarin, oral contraceptives, acetaminophen, ACE inhibitors, statins and digoxin, the pattern was a lower peak concentration and a later time to peak, with no clinically significant change in total exposure (area under the curve). No antidepressant was among the drugs studied. For a drug taken every day at a steady dose, total exposure is what matters most, which is why clinicians generally expect antidepressant levels to hold; it remains an expectation rather than a measured finding.
Frequently Asked Questions
Is it safe to take tirzepatide with antidepressants?
For most patients the combination is used without a documented problem. The Zepbound and Mounjaro labels (08/2026) list no specific interaction with SSRIs, SNRIs or bupropion, but section 7.2 cautions that tirzepatide delays gastric emptying and can affect absorption of oral medicines, and asks prescribers to monitor drugs that depend on threshold concentrations. Your prescriber should know about all your current medications.
Does tirzepatide affect antidepressant absorption?
Tirzepatide delays gastric emptying, which can slow the rate at which oral medications reach peak blood levels. A 2024 Drug Safety systematic review found that for the oral drugs actually studied with GLP-1 agonists, peak levels fell and were delayed but total exposure did not change meaningfully. Antidepressants were not among the drugs studied, so this is an inference, not a measured result.
Can tirzepatide worsen anxiety or depression?
The Zepbound label carried a warning on suicidal behavior and ideation until February 2026, when Lilly removed it; the 08/2026 label lists that removal under Recent Major Changes. An earlier version of this answer also claimed the SURMOUNT and SURPASS trials showed no increase in depression or anxiety; that statement was unsourced and has been removed. Report any new or worsening mood symptoms to your prescriber regardless.
Should I tell my psychiatrist I am starting tirzepatide?
Absolutely. Both your prescribing physician for tirzepatide and your mental health provider should be aware of all your medications. This allows coordinated monitoring and prompt adjustment if any issues arise.
Can I take sertraline (Zoloft) with tirzepatide?
The Zepbound and Mounjaro labels (revised 08/2026) do not list sertraline or any SSRI as an interacting drug; the only relevant label language is the general section 7.2 caution that delayed gastric emptying can affect absorption of oral medicines. No pharmacokinetic study of sertraline with tirzepatide has been published. Both drugs can cause nausea, so tell both prescribers and consider starting them at different times to sort out side effects.
Do I need to change when I take my antidepressant if I start tirzepatide?
The labels give no timing instruction for antidepressants; the only oral-drug timing rule in section 7.2 concerns hormonal contraceptives (add a barrier method for 4 weeks after starting and after each dose increase). A 2024 Drug Safety review found GLP-1 agonists delayed peak levels of studied oral drugs without changing total exposure, so most clinicians keep the antidepressant schedule unchanged. Do not adjust doses or timing without your prescriber.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
thorough Care at FormBlends
FormBlends providers review your complete medication profile before prescribing tirzepatide. We coordinate with your existing providers to ensure safe, effective treatment that supports both your weight loss goals and your mental health.
Sources
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, revised 08/2026 (Recent Major Changes; section 7.2 Oral Medications; section 14). https://pi.lilly.com/us/zepbound-uspi.pdf
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information, revised 08/2026 (section 7.2). https://pi.lilly.com/us/mounjaro-uspi.pdf
- Novo Nordisk. Wegovy (semaglutide) prescribing information, revised 06/2026 (section 7.2). https://www.novo-pi.com/wegovy.pdf
- Calvarysky B et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf 2024;47:439-451. https://europepmc.org/article/MED/38273155
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. https://europepmc.org/article/MED/35658024
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331:38-48. https://europepmc.org/article/MED/38078870
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →